Drug intelligence / Profile preview

Coryza ABC

Development stage: Unknown
Lead developer: Navana Pharmaceuticals
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

Coryza ABC (specifically marketed as ITA Coryza ABC Gel) is an inactivated veterinary vaccine developed by Laprovet and distributed by Navana Pharmaceuticals. It is designed for the active immunization of poultry, particularly breeder and layer-type chicken flocks, against infectious coryza caused by *Avibacterium paragallinarum*. The vaccine contains inactivated cultures of *Avibacterium paragallinarum* serotypes A, B, and C, homogenized with an aluminum hydroxide gel adjuvant. It is administered subcutaneously or intramuscularly to chickens between 8 and 12 weeks of age to prevent clinical signs of infectious coryza, such as swelling of the face and wattles, nasal discharge, and respiratory distress.

Brand names: ITA Coryza ABC Gel
Other names: ITA Coryza ABCInfectious coryza vaccine

Beyond the preview

Go deeper on Coryza ABC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coryza ABC.